This announcement is a separate document:
雲頂新耀-B：自願公告 最新業務情況 有關耐賦康用於治療成人患者具有進展風險的原發性IgA腎病的新藥上市申請在中國獲批
EVEREST MED-B: VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE APPROVAL OF NEW DRUG APPLICATION IN CHINA FOR NEFECON FOR THE TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY IN ADULTS AT RISK OF DISEASE PROGRESSION
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.